My Website

Changing the world, one site at a time…

Sidebar
Menu

Case Studies 

Case Study 1
A private mid-sized biotech company with 250 employees and an internal medicinal chemistry department approached MedChem Partners to help them in their drug discovery efforts. To facilitate in vivo work, the company needed to have stable isotope derivatives of several lead compounds prepared, but did not have the internal resources for the task.

The company engaged MedChem Partners to prepare the stable isotope analogues and MedChem Partners was able to assess the chemistry, quote a price and begin chemistry within two weeks.

The two compounds were delivered rapidly and in high purity, which allowed the timely completion of the in vivo work. Based on quality of the work, the company then retained MedChem Partners to expand on the project and make a small library of compounds for SAR and testing.

MedChem Partners and the company entered into an FTE relationship for the ongoing iterative production of small libraries to develop back-up compounds to the leads currently under development.
Case Study 2
Company X is a pre-funding stage start-up based in a university incubator. The company has two compound hits, which work as novel antibiotics in the initial screen. The company does not have the internal resources nor the experience to develop these candidates.

MedChem Partners reviewed all of the data and worked with company X to prepare a comprehensive plan for development of the two hit compounds. The plan included a strategy for primary and secondary in vitro assays, preliminary eADME work and in vivo testing. The compounds were ranked according to the established selection criteria. In addition, MedChem Partners addressed the patent strategy and developed a chemistry route that allowed for rapid generation of analogs for SAR and optimization of PK/PD properties.

MedChem Partners prepared a small library of compounds to explore the SAR around the initial hits. Based on the information generated from this initial data set, a second library was designed to optimize for biological activity and solubility.

In addition to this project, MedChem Partners worked with Company X to prepare the due diligence scientific plan and presentations required for the initial round of financing.

Top

Case Study 3
A small biotech with seed funding and a novel application for a known compound retained MedChem Partners to help with the development of the new indication.

The Company wanted to begin lead optimization on the compound right away, however, following the advice of MedChem Partners, an initial assessment of the program was undertaken. The assessment revealed that the initial compound's synthesis was problematic, there was very little IP space, and the compound contained several potentially toxic functionalities. MedChem Partners suggested an alternate structure which was easy to synthesize from commercially available advanced intermediates, readily functionalized, and did not possess the liabilities of the original core structure.

MedChem Partners prepared a small library based on the new structure and found one compound which was equipotent to the initial lead compound.

Based on the positive results, MedChem Partners was hired to expand on the original hit compound and continue lead optimization on the new core structure
Case Study 4
An academic laboratory at a major university had discovered a novel therapeutic target and found several weak hits in a high throughput screen. Based on their early successes, they were encouraged to initiate a drug discovery program to develop novel therapeutics against this target. The initial HTS hits showed activity against the desired target in both enzyme and cell based assays. The researchers were interested in applying for internal university funding to initiate a medicinal chemistry hit-to-lead optimization program.

MedChem Partners worked with the academic group to create a comprehensive medicinal chemistry development plan including: ranking of hits, weeding out of potentially problematic structures, initial substructure patent searching, designing a synthetic route for the core structures and a plan for rapid analog generation. In addition, MedChem Partners presented the proposal to the university funding chair, and assisted the academic researchers defending the project.

The proposal was funded by the university and MedChem Partners was retained in an FTE relationship to implement the medicinal chemistry plan and help guide the program forward. MedChem Partners designed and validated the synthesis of the core structures and prepared several focused libraries to define the SAR of these series. Several iterative rounds of medicinal chemistry and screening were performed until the defined program milestones were reached.

This program continues to move forward with the ultimate goal of finding angel or venture funding to spin out as start-up.

MedChem Partners continues to manage and implement the medicinal chemistry for this project as well as assisting in the preparation of due diligence reports and in the funding process as needed.

Top

Menu